Type-1 insulin-like growth factor receptor reexpression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis.

Type-1 insulin-like growth factor receptor reexpression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis.
复制标题

SV40-T 永生化人前列腺上皮细胞恶性表型中 1 型胰岛素样生长因子受体的重新表达可增强细胞凋亡。

DOI:
10.1007/bf02778078
复制
发表时间:
1997
期刊:
影响因子:
3.7
通讯作者:
Ware,JL
Ware,JL
中科院分区:
医学3区
文献类型:
--
作者:
Plymate,SS;Bae,VL;Maddison,L;Quinn,LS;Ware,JL

文献摘要

相似文献

作者此前已证明,1型胰岛素样生长因子受体(IGF-1R)在体内人前列腺上皮细胞从良性向恶性转化的过程中减少。此外,在一个详细描述的人类SV40-T永生化人上皮细胞系统中,从永生化但很少致瘤的P69SV40-T细胞系开始,到高度致瘤和转移的M12亚系,IGF-1R数量有类似的减少,从每个细胞2.0×104个受体到每个细胞1.1×103个受体。当使用逆转录病毒表达载体 M12-LISN 在 M12 亚系中将 IGF-1R 重新表达到与 P69SV40-T 亲本细胞系相似的受体数量时,作者证明,与 M12 对照细胞相比,M12-LISN 细胞中软琼脂中的集落形成显着减少(p≤0.01),并且当皮下或前列腺内注射时,体内肿瘤生长和转移减少(p≤0.01)。肿瘤体积的减小并不是由于增殖能力的降低,而是与基线培养物中细胞凋亡的增加以及细胞凋亡诱导剂 6-羟基脲、视黄酸和转化生长因子 β1 的反应有关。
The authors have previously shown that the type 1 insulin-like growth factor receptor (IGF-1R) is decreased in the transformation from benign to malignant human prostate epithelial cells in vivo. Further, in a well-described human SV40-T immortalized human epithelial cell system beginning with the immortalized, but rarely tumorigenic P69SV40-T cell line, to the highly tumorigenic and metastatic M12 subline, there is a similar decrease in IGF-1R number from 2.0×104receptors per cell to 1.1×103receptors per cell. When the IGF-1R was reexpressed in the M12 subline using a retroviral expression vector, M12-LISN, to a receptor number similar to that of the P69SV40-T parental cell line, the authors demonstrated a marked decrease in colony formation in soft agar in the M12-LISN cells vs the M12 control cells (p≤0.01), and a decrease in vivo tumor growth and metastases when injected either subcutaneously or an intraprostatic location (p≤0.01). This decrease in tumor volume was not because of a decrease in proliferative capacity, but was associated with an increase in apoptosis in baseline cultures and in response to the apoptotic-inducing agents 6-hydroxyurea, refinoic acid, and transforming growth factor β1.